Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis

PURPOSE: REACH investigated second-line ramucirumab therapy for advanced hepatocellular carcinoma. RESULTS: Median overall survival was 8.2 months for ramucirumab and 6.9 months for placebo (HR, 0.835; 95% CI, 0.634–1.100; p = 0.2046) for East Asians, and 10.1 months for ramucirumab and 8.0 months f...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Park, Joon Oh, Ryoo, Baek-Yeol, Yen, Chia-Jui, Kudo, Masatoshi, Yang, Ling, Abada, Paolo B., Cheng, Rebecca, Orlando, Mauro, Zhu, Andrew X., Okusaka, Takuji
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342754/
https://ncbi.nlm.nih.gov/pubmed/27776351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12780
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky